Concert AI has raised a total of $300 million across two funding rounds a $150 million Series B in January 2020 led by Declaration Partners, Maverick Ventures, AllianceBernstein, and SymphonyAI, and a $150 million Series C in March 2022 led by Sixth Street - reaching a $1.9 billion valuation. Founded in 2018 and headquartered in Boston, Massachusetts, Concert AI leverages artificial intelligence to deliver oncology data insights, clinical trial matching, and research optimization for biopharma and healthcare organizations, advancing precision oncology and improving patient outcomes worldwide.